Kura Oncology’s (KURA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities restated their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a $32.00 price target on the stock.

KURA has been the topic of a number of other reports. StockNews.com downgraded Kura Oncology from a hold rating to a sell rating in a research report on Monday, April 15th. Wedbush reiterated an outperform rating and set a $37.00 target price on shares of Kura Oncology in a research report on Friday, May 3rd. Finally, HC Wainwright restated a buy rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Friday, May 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $28.28.

Kura Oncology Stock Performance

NASDAQ KURA opened at $20.55 on Monday. The business has a 50-day moving average price of $20.63 and a 200-day moving average price of $16.25. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -9.47 and a beta of 0.89. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03). The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.50) EPS. As a group, equities research analysts predict that Kura Oncology will post -2.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently added to or reduced their stakes in the company. Entropy Technologies LP purchased a new position in Kura Oncology during the 1st quarter valued at $218,000. ProShare Advisors LLC grew its holdings in shares of Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after purchasing an additional 1,588 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Kura Oncology in the 1st quarter worth about $507,000. SG Americas Securities LLC purchased a new stake in Kura Oncology in the 1st quarter valued at about $110,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Kura Oncology by 12.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,970 shares of the company’s stock worth $874,000 after acquiring an additional 4,659 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.